Can an app predict epileptic seizures? new study aims to find out
NCT ID NCT07068919
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study will test whether a mobile app called EPIDAY can predict the daily risk of epileptic seizures in 50 adults with focal epilepsy. Participants will use the app to report symptoms and track seizures for three months. The goal is to see if machine learning can turn these reports into useful risk predictions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
EPIDAY mobile application
What this could lead to
If successful, this could lead to a tool that helps people with epilepsy anticipate seizure risk and plan their day.
What could go wrong
This is a small, early-stage study with only 50 participants. The predictions may not be accurate enough for real-world use, and the app relies on self-reported symptoms, which can vary.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPILEPSY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hôpital Pitié-Salpêtrière, AP-HP
Paris, 75013, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact